Long-term safety and efficacy data from a continuation study of Benlysta in patients with systemic lupus erythematosus (SLE) has been released.
Tobacco smoking adversely impacts rheumatoid arthritis (RA) flare and remission rates, according to findings from a long-term retrospective, population-based cohort study, presented at the 2016 ACR/ARHP Annual Meeting.
Temporarily discontinuing methotrexate (MTX) treatment can improve seasonal influenza vaccination immunogenicity among patients with rheumatoid arthritis (RA), according to a single center, randomized, single-blind, open-label prospective study (NCT02748785) presented at the 2016 ACR/ARHP Annual Meeting.
Results from a global survey given to patients and physicians showed that good communication is "critical to achieve optimal care".
The IL-6Rα -targeting human mAb sarilumab offers durable responses against rheumatoid arthritis (RA), according to an analysis of 3-year clinical and radiographic outcomes and safety for patients from the MOBILITY open-label extension study.
The IL-6Rα -targeting human mAb sarilumab exhibits comparable efficacy and safety for different patient subgroups in rheumatoid arthritis.
Adalimumab (Humira) helps treat non-infectious intermediate, posterior, or panuveitis (NIPPU), according to findings from an open-label clinical trial extension, VISUAL-III
For RA patients with interstitial lung disease, rituximab linked to improved survival versus TNFi
Tumor necrosis factor (TNF) inhibitors yield promising responses among patients with chronic, recurring-abscessing sweat-gland inflammation known as hidradenitis suppurativa (HS).
Several recent studies have shown that a delay in diagnosis of PsA leads to a worse outcome.
The objective was to determine the clinical effects of Otezla vs. placebo through its early efficacy outcomes
Use of febuxostat (FBX) might cause skin reactions in some patients with gout who have experienced such reactions after allopurinol administration.
Uveitis should be suspected in patients with ankylosing spondylitis (AS) who have high lesion counts, antistreptolysin O (ASO) and circulating immune complex (CIC) titers
Treatment of psoriatic arthritis (PsA) with ixekizumab (IXE)—an IgG4 monoclonal antibody—significantly improves arthritis, dactylitis and enthesitis at 52-weeks
Cycling to a different tumor necrosis factor alpha inhibitor (TNFi) after treatment failure in patients with rheumatoid arthritis (RA) can be effective.
Juvenile idiopathic arthritis (JIA)-associated uveitis was well-controlled with adalimumab and/or methotrexate.
Glucosamine sulfate is the only agent consistently effective on symptoms and joint structure changes in patients with knee osteoarthritis (OA).